Retrospective database analysis of healthcare resource utilization and costs in patients who develop post-transplant lymphoproliferative disease within the first year following allogeneic hematopoietic stem cell transplants

References

• Cleary ML, Nalesnik MA, Shearer WT, et al. Clonal analysis of transplant-associated lymphoproliferations based on the structure of the genomic termini of the Epstein-Barr virus. Blood. 1988;72(1):349–352.
   PubMed Web of Science ®Google Scholar
• Shapiro RS, McClain K, Frizzera G, et al. Epstein-Barr virus associated B cell lymphoproliferative disorders following bone marrow transplantation. Blood. 1988;71(5):1234–1243.
   PubMed Web of Science ®Google Scholar
• Al-Mansour Z, Nelson BP, Evens AM. Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies. Curr Hematol Malig Rep. 2013;8(3):173–183.
   PubMed Web of Science ®Google Scholar
• Epstein MA, Achong BG, Barr YM. Virus particles in cultured lymphoblasts from Burkitt’s lymphoma. Lancet. 1964;1(7335):702–703.
   PubMedGoogle Scholar
• Uhlin M, Wikell H, Sundin M, et al. Risk factors for Epstein-Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica. 2014;99(2):346–352.
   PubMed Web of Science ®Google Scholar
• Curtis RE, Travis LB, Rowlings PA, et al. Risk of lymphoproliferative disorders after bone marrow transplantation: a multi-institutional study. Blood 1999;94:2208–2216.
   Google Scholar
• Styczynski J, Gil L, Tridello G, et al. Response to rituximab-based therapy and risk factor analysis in Epstein Barr Virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis. 2013;57(6):794–802.
   PubMed Web of Science ®Google Scholar
• Alexander DD, Mink PJ, Adami HO, et al. The non-Hodgkin lymphomas: a review of the epidemiologic literature. Int J Cancer. 2007;120(12):1–39.
   PubMedGoogle Scholar
• Fox CP, Burns D, Parker AN, et al. EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. Bone Marrow Transplant. 2014;49(2):280–286.
   PubMed Web of Science ®Google Scholar
• Ocheni S, Kroeger N, Zabelina T, et al. EBV reactivation and post transplant lymphoproliferative disorders following allogeneic SCT. Bone Marrow Transplant. 2008;42(3):181–186.
   PubMed Web of Science ®Google Scholar
• Katz A, Barlev A, Joshi AJ. Burden of post-transplant lymphoproliferative disorder-mortality after allogeneic hematopoietic cell transplantation. Bone Marrow Transplantation 2018. Supplement: 44th Annual EBMT Meeting Abstracts, p. P218.
   Google Scholar
• Bentley T, Phillips S. 2017 U.S. organ and tissue transplant cost estimates and discussion. Seattle WA: Milliman Inc.; 2017 [cited 2020 Jul 13]. (Milliman Research Report). Available from: https://www.milliman.com/en/Insight/2017-US-organ-and-tissue-transplant-cost-estimates-and-discussion
   Google Scholar
• Kasiske BL, Kukla A, Thomas D, et al. Lymphoproliferative disorders after adult kidney transplant: epidemiology and comparison of registry report with claims-based diagnoses. Am J Kidney Dis. 2011;58(6):971–980.
   PubMed Web of Science ®Google Scholar
• Paramore LC, Thomas SK, Knopf KB, et al. Estimating costs of care for patients with newly diagnosed metastatic colorectal cancer. Clin Colorectal Cancer. 2006;6(1):52–58.
   PubMed Web of Science ®Google Scholar
• Song X, Zhao Z, Barber B, et al. Characterizing medical care by disease phase in metastatic colorectal cancer. J Oncol Pract. 2011;7(3):25s–30s.
   PubMedGoogle Scholar
• Hopson S, Casebeer A, Stemkowski S, et al. Does site-of-care for oncology infusion therapy influence treatment patterns, cost, and quality in the United States? J Med Econ. 2018;21(2):152–162.
   PubMed Web of Science ®Google Scholar
• Weycker D, Hatfield M, Grossman A, et al. Risk and consequences of chemotherapy-induced thrombocytopenia in US clinical practice. BMC Cancer. 2019;19(1):151.
   PubMedGoogle Scholar
• Kawatkar AA, Farias AJ, Chao C, et al. Hospitalizations, outcomes, and management costs of febrile neutropenia in patients from a managed care population. Support Care Cancer. 2017;25(9):2787–2795.
   PubMed Web of Science ®Google Scholar
• Stein EM, Bonifacio G, Latremouille-Viau D, et al. Treatment patterns, healthcare resource utilization, and costs in patients with acute myeloid leukemia in commercially insured and Medicare populations. J Med Econ. 2018;21(6):556–563.
   PubMed Web of Science ®Google Scholar
• Bonafede M, Richhariya A, Cai Q, et al. Real-world economic burden of hematopoietic cell transplantation among a large US commercially insured population with hematologic malignancies. J Med Econ. 2017;20(12):1244–1251.
   PubMed Web of Science ®Google Scholar
• Broder MS, Quock TP, Chang E, et al. The cost of hematopoietic stem-cell transplantation in the United States. Am Health Drug Benefits. 2017;10:366–374.
   PubMed Web of Science ®Google Scholar
• Cancer Stat Facts: Non-Hodgkin Lymphoma [Internet]. Bethesda (MD): National Cancer Institute; 2019 [cited 2019 April 8]. Available from: https://seer.cancer.gov/statfacts/html/nhl.html
   Google Scholar
• National Research Council. Aging and the Macroeconomy. Long-term implications of an older population. Committee on the Long-Run Macroeconomic Effects of the Aging U.S. Population. Board on Mathematical Sciences and their Applications, Division on Engineering and Physical Sciences, and Committee on Population, Division of Behavioral and Social Sciences and Education, Washington, DC; 2012.
   Google Scholar
• Posluszny DM, Bovbjerg DH, Syrjala KL, et al. Correlates of anxiety and depression symptoms among patients and their family caregivers prior to allogeneic hematopoietic cell transplant for hematological malignancies. Support Care Cancer. 2019;27(2):591–600.
   PubMed Web of Science ®Google Scholar
• Grant M, Cooke L, Williams AC, et al. Functional status and health-related quality of life among allogeneic transplant patients at hospital discharge: a comparison of sociodemographic, disease, and treatment characteristics. Support Care Cancer. 2012;20(11):2697–2704.
   PubMed Web of Science ®Google Scholar
• Oerlemans S, Mols F, Nijziel MR, et al. The course of anxiety and depression for patients with Hodgkin’s lymphoma or diffuse large B cell lymphoma: a longitudinal study of the PROFILES registry. J Cancer Surviv. 2014;8(4):555–564.
   PubMed Web of Science ®Google Scholar
• Carlson LE, Angen M, Cullum J, et al. High levels of untreated distress and fatigue in cancer patients. Br J Cancer. 2004;90(12):2297–2304.
   PubMed Web of Science ®Google Scholar